Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.

Neuro-oncology - 11 Jan 2020

Arrillaga-Romany Isabel, Odia Yazmin, Prabhu Varun V, Tarapore Rohinton S, Merdinger Krystal, Stogniew Martin, Oster Wolfgang, Allen Joshua E, Mehta Minesh, Batchelor Tracy T, Wen Patrick Y

Abstract excerpt

BACKGROUND: ONC201 is a dopamine receptor D2 (DRD2) antagonist that penetrates the blood-brain barrier. ONC201 efficacy has been shown in glioblastoma animal models and is inversely correlated with dopamine receptor DRD5 expression. ONC201 is well tolerated in adult recurrent glioblastoma patients with dosing every 3 weeks and has achieved an objective radiographic response in a patient harboring the H3 K27M...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histones

Share to Imidazoles

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Share to Pyridines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 31702782
DOI: 10.1093/neuonc/noz164
PMCID: PMC7080220

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.PMID 31702782Read ↗

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.Semantic proximity Read ↗

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.Semantic proximity Read ↗

Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in GlioblastomaSemantic proximity Read ↗

Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline gliomaSemantic proximity Read ↗

Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitorsSemantic proximity Read ↗

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 AntagonismSemantic proximity Read ↗

Combination of Imipridone ONC201 or ONC206 with Temozolomide and Radiotherapy in triple ITR therapy reduces intracranial tumor burden and prolongs survival in an orthotopic wild-type IDH GBM mouse modelSemantic proximity Read ↗

Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastomaSemantic proximity Read ↗

Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.Semantic proximity Read ↗

Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastomaSemantic proximity Read ↗

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.Semantic proximity Read ↗

Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS ExposureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.